{"nctId":"NCT00622843","briefTitle":"Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting","startDateStruct":{"date":"2002-12"},"conditions":["HIV Infections","Streptococcus Pneumoniae"],"count":275,"armGroups":[{"label":"Group 1","type":"EXPERIMENTAL","interventionNames":["Biological: pneumococcal conjugate vaccine"]},{"label":"Group 2","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: pneumococcal polysaccharide vaccine"]},{"label":"Group 3","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: pneumococcal conjugate vaccine"]}],"interventions":[{"name":"pneumococcal conjugate vaccine","otherNames":["PCV"]},{"name":"pneumococcal polysaccharide vaccine","otherNames":["PPV"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for HIV positive subjects:\n\n1. At least one prior PPV ≥ 3 and \\< 8 years ago, while HIV positive. There is no upper limit to the number of previously received PPVs.\n2. HIV-positive (except 25 HIV-negative persons as control group).\n3. Age between 18 and 60 years of age.\n4. Availability of patient to remain within the immediate area for the period of the study and be able to comply with protocol requirements.\n\nExclusion Criteria for HIV positive subjects:\n\n1. Prior allergic reaction to the PPV\n2. Allergic to components of PCV, including diphtheria toxin.\n3. Pregnant or lactating females as defined by history or positive HCG urine test.\n4. History of chronic viral hepatitis or biochemical evidence to include pretreatment AST or ALT values greater than 3 fold higher than upper limit of normal, or a creatinine of greater than 1.8 mg/dl\n5. History of splenectomy\n6. Temperature of \\>38C\n7. Inability to ambulate for more than 1000 meters secondary to fatigue, pain or weakness.\n8. Patients in whom IM vaccination is not possible because of disease or medication. (e.g. hemophilia, coumadin therapy).\n9. Patients diagnosed with HIV wasting disease\n10. Viral load over 50,000 copies/ml.\n11. History or evidence of recent illicit drug or alcohol abuse.\n12. Use of immunosuppressive agents, to include corticosteroids and cancer chemotherapeutic agents.\n\nInclusion Criteria for HIV negative subjects:\n\n1. HIV-negative by HIV ELISA within the last 12 months\n2. Age between 18 and 60 years of age.\n3. Availability of patient to remain within the immediate area for the period of the study and be able to comply with protocol requirements.\n\nExclusion Criteria for HIV negative subjects:\n\n1. Prior PCV and/or PPV vaccination.\n2. Prior allergic reaction to the PPV\n3. Allergic to components of PCV, including diphtheria toxin.\n4. Pregnant or lactating females as defined by history or positive HCG urine test.\n5. History of chronic viral hepatitis or biochemical evidence to include pretreatment AST or ALT values greater than 3 fold higher than upper limit of normal, or a creatinine of greater than 1.8 mg/dl\n6. History of splenectomy\n7. Temperature of \\>38C\n8. Inability to ambulate for more than 1000 meters secondary to fatigue, pain or weakness.\n9. Patients in whom IM vaccination is not possible because of disease or medication. (e.g. hemophilia, coumadin therapy).\n10. History or evidence of recent illicit drug or alcohol abuse.\n11. Use of immunosuppressive agents, to include corticosteroids and cancer chemotherapeutic agents.\n12. Works in chain of command of primary/associate investigators.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Positive Immune Responses in the Human Immunodeficiency Virus (HIV)-Infected Pneumococcal Conjugate Vaccine (PCV) and Pneumococcal Polysaccharide Vaccine (PPV) Arms","description":"The primary end point is greater than or equal to a 2-fold increase in the IgG level for at least 2 of the 4 serotypes on day 60, with levels greater than or equal to 1000 ng/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"PRIMARY","title":"Adverse Events (AEs) Occurring Temporally (Within 7 Days) in Association With Pneumococcal Vaccination","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of CD4+ Cell Count Changes Caused by Vaccination With PCV and PPV.","description":"The pairwise change in CD4+ cell count from the time of screening to each time frame (day 14, day 60 and day 180 post-vaccination) (CD4+ cell count at day 14/60/180 \\[minus\\] CD4+ cell count at screening).\n\nAnalysis Population Description (further details): not all participants completed each follow-up visit. Therefore, a different number of participants analyzed is noted for each visit day. For example, in Group 1, 131 participants completed the screening visit but only 129 completed Day 14, and only 123 completed Day 60, etc.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.17","spread":"22.29"},{"groupId":"OG001","value":"14.66","spread":"28.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.20","spread":"21.13"},{"groupId":"OG001","value":"22.57","spread":"30.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.65","spread":"21.57"},{"groupId":"OG001","value":"12.22","spread":"27.81"}]}]}]},{"type":"SECONDARY","title":"Assessment of the Importance of the Host Immune Status (CD4+ Count) on the PCV and PPV Immunologic Response.","description":"Number with ≥ Successes, which is defined as: Success = 2-fold increase on Log10 scale -- if log10(Day 60) - log10(Screening) \\> log10(2)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Viral Load Changes Caused by Vaccination With PCV and PPV.","description":"The pairwise change in viral load from the time of screening to each time frame (day 14, day 60 and day 180 post-vaccination), similar to CD4 change above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.08"},{"groupId":"OG001","value":"0.03","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.08"},{"groupId":"OG001","value":"0.08","spread":"0.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.09"},{"groupId":"OG001","value":"0.01","spread":"0.13"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":131},"commonTop":["Local tenderness","Myalgia","Malaise","Local site reaction","Headache"]}}}